Simon Tilley, global lead for healthcare and life sciences at SAS, breaks down the benefits and drawbacks of decentralised clinical trials (DCT). He also explains how AI, machine learning and advanced analytics can refine all stages from participant recruitment to compiling results to ensure the best outcomes are achieved.
Key insights:
- Decentralised trial designs can provide a high testing and monitoring frequency of its participants, as well as more inclusive and representative of the people who will use the drug.
- DCTs is a double edge sword as it can also deliver a large volume and variety of data which can become overwhelming for manual data entry.
- AI and machine learning can overcome limitations of DCTs by processing large amounts of data quickly, and predicting participant drop out probability.
Remote data capture, through using wearable technology for instance, opens the door for large-scale studies to be undertaken without the need for participants to always be based in a testing facility.